ArticleBMC cancer2026
The impact of STAS on recurrence-free and overall survival in T1-2N0 adenocarcinomas: a single-center retrospective study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenocarcinoma (AC) is the leading histopathological type of lung cancer (LC), curative surgery being the cornerstone for the best survival results. However, even in the patients who had curative surgery, the survival outcomes differ. Spread through air spaces (STAS), recognized as a histopathological feature in the 2015 World Health Organization (WHO) Classification, causes poor survival outcomes in lung AC. This study aimed to evaluate the prognostic impact of STAS on recurrence-free survival (RFS) and overall survival (OS) in surgically resected T1-2N0 lung AC, with particular attention to its interaction with tumor size.
methodsThis single center retrospective study evaluates the effect of STAS on RFS and OS in 296 surgically resected T1-2N0 lung AC patients. For further analysis, patients were divided into four subgroups combining their STAS status and tumor size.
resultsSTAS presence rate was 37.5%, which was associated with aggressive tumor characteristics, such as non-lepidic predominant subtypes, higher pathological T stage (pT), visceral pleura invasion (VPI), and lymphovascular invasion (LVI). OS and RFS were significantly worse in the STAS-Present (STAS-P) group (p = 0.030). Subgroup analysis revealed that STAS-P tumors > 2 cm had the worst outcomes, as expected. Notably, on univariate analysis STAS presence appeared most prognostically decisive in tumors ≤ 2 cm, in which there was no significant difference in survival between STAS-P tumors ≤ 2 cm and STAS-Absent (STAS-A) tumors > 2 cm.
conclusionsSTAS was a significant prognostic factor on univariate analysis but did not retain independent significance after multivariable adjustment. In an exploratory subgroup analysis, STAS-P tumors ≤ 2 cm carried survival outcomes comparable to STAS-A tumors > 2 cm, suggesting STAS may attenuate the prognostic advantage of smaller tumor size. This hypothesis-generating finding warrants prospective validation before informing surgical management.
Indexed as
Identifiers
42919260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.